Compare Adaptive Biotechnologies Corp (ADPT) vs Carvana Co (CVNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Carvana Co — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Carvana Co trades at $65.64 (market cap $48.34B). The key difference: Carvana Co is far larger — about 14.5× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| ADPT | CVNA | |
|---|---|---|
Market Cap | $3.33B | $48.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $95.69 |
52-Week Low | $10.24 | $56.27 |
Enterprise Value | $3.19B | $50.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Carvana (CVNA) trades at $67.47, down 1.63% on the day, with a bullish technical signal and strong fundamental growth. Revenue surged to $20.32B in 2025, with net income reaching $1.41B, though Q2 2026 earnings are pending. Recent corporate actions include stock splits, and expansion news includes same-day delivery in Milwaukee.
The outlook is positive with analyst consensus at Buy and a $93.92 price target, but risks include high debt levels and competitive pressures. Upside potential exists from operational efficiency and market expansion, yet volatility from used-car market softness remains a concern for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
